eGFR-cystatin-C is a derived estimate of kidney filtration function based on serum cystatin C concentration, using the CKD-EPI-cystatin or CAPA equations. It reflects how efficiently your kidneys remove waste from the bloodstream and is particularly accurate in people with atypical muscle mass — athletes, the elderly, amputees, and those with sarcopenia. Unlike creatinine-based eGFR, cystatin-C-based eGFR is independent of muscle bulk and is a stronger predictor of both cardiovascular and all-cause mortality in many cohorts.
This is a derived biomarker — calculated from directly measured serum cystatin C values.
Analyzed in accredited Swedish clinical laboratories (ISO 15189). Used to support clinician-directed evaluation and monitoring. Not a stand-alone diagnosis.
Kidney function underlies almost every aspect of longevity — waste clearance, blood pressure regulation, mineral metabolism, and hormone signaling all depend on healthy glomerular filtration. A standard annual kidney screen at your vårdcentral measures creatinine and estimates eGFR using creatinine, but that test can mislead you if your muscle mass is atypical: it will overestimate kidney function in the elderly or sarcopenic, and underestimate it in athletes or people with high muscle bulk.
If you fall into any of those categories, or if you want the most accurate longevity-relevant measure of kidney function, testing eGFR via cystatin C gives you a clearer picture. It is also a stronger predictor of cardiovascular and all-cause mortality than creatinine-based eGFR, making it uniquely valuable in a longevity context. Swedish nephrology (LMREV) specifically recommends cystatin-C-based eGFR or combined eGFR when muscle mass is atypical.
Measures kidney filtration independent of muscle mass. Cystatin C is produced at a constant rate by all nucleated cells, making it free from the confounding effects of muscle bulk that plague creatinine-based estimates.
Flags hidden renal decline in athletes and the elderly. Creatinine-based eGFR can mask declining kidney function in people with low muscle mass; cystatin-C-based eGFR catches it earlier and more accurately.
Predicts cardiovascular and all-cause mortality more strongly. Numerous cohort studies show that eGFR-cystatin-C is a better prognostic marker for both cardiovascular events and overall survival than creatinine-based eGFR, particularly in people without established chronic kidney disease.
Identifies confounding variables that affect renal interpretation. Hyperthyroidism, hypothyroidism, glucocorticoid use, and obesity can all shift cystatin-C levels independent of true filtration — pairing it with creatinine-based eGFR helps resolve these.
Guides the choice between cystatin-C-only and combined (average) eGFR. When cystatin-C and creatinine-based eGFR differ by more than ~20%, a blended estimate is often more reliable than either alone.
Tracks longitudinal renal health in proactive longevity protocols. Repeated testing over years reveals subtle decline before overt dysfunction, informing cardiovascular risk management and medication choices.
The molecule and its production. Cystatin C is a small protease inhibitor produced by all nucleated cells at a roughly constant rate, regardless of age, sex, or muscle mass. It is freely filtered by the glomerulus and reabsorbed (but not secreted) by the renal tubules. Because its production is stable and independent of muscle bulk, it is theoretically a cleaner marker of true glomerular filtration than creatinine, which depends heavily on muscle turnover.
The equations. eGFR-cystatin-C is calculated using either the CAPA (Chronic Kidney Disease Epidemiology Collaboration — cystatin C and creatinine combined) or CKD-EPI-cystatin equations, which take serum cystatin C concentration and apply age (and sometimes additional variables) to estimate the volume of fluid filtered per minute per 1.73 m² of body surface area. The result is expressed in mL/min/1.73m², the standard unit across Europe and Sweden.
Why it differs from creatinine-based eGFR. Serum creatinine reflects muscle turnover — muscle breaks down, releases creatinine, and the kidneys filter it. In an athlete with high muscle mass, creatinine is produced copiously, so serum creatinine stays low and creatinine-based eGFR overestimates true kidney function. In an elderly or sarcopenic person, muscle is sparse, creatinine production is low, and creatinine-based eGFR can mask significant decline. Cystatin C bypasses this problem because it is made by all cells at a steady rate, independent of muscle.
Mortality prediction. Large prospective cohorts (NHANES, CHS, Framingham) have shown that eGFR-cystatin-C predicts cardiovascular events and all-cause mortality more strongly than creatinine-based eGFR, even in people with apparently normal kidney function. This makes it a valuable longevity marker alongside traditional renal parameters.
Identifies silent renal decline when it matters most. Kidney function declines gradually with age, but creatinine-based eGFR can hide it in people with low muscle. Cystatin-C-based eGFR catches the decline earlier, when intervention (blood pressure management, SGLT2 inhibition, glycemic control) is most effective.
Reveals discordance between biomarkers that signals metabolic complexity. When eGFR-creatinine and eGFR-cystatin-C diverge significantly, it often points to thyroid dysfunction, glucocorticoid exposure, severe obesity, or other confounders that matter for overall health. Recognizing this pattern arms you (and your doctor) with diagnostic clues.
Predicts cardiovascular risk beyond traditional lipid panels. Declining kidney function is a powerful independent predictor of heart disease and stroke. eGFR-cystatin-C is more sensitive to this risk than creatinine-based eGFR, so it refines your cardiovascular assessment, particularly when paired with markers like hs-CRP, LDL, and Lp(a).
Informs medication safety and pharmacokinetics. Kidney function dictates how the body clears medications. Accurate eGFR prevents drug accumulation, ensures optimal dosing of renally cleared drugs (metformin, GLP-1 agonists, ACE inhibitors, diuretics), and flags need for dose adjustment earlier than creatinine-based estimates would.
Standard Swedish reference (vårdcentralen): > 60 mL/min/1.73m² is considered normal kidney function for adults; < 60 signals chronic kidney disease and warrants investigation.
Loovi optimal (longevity proactive): > 80 mL/min/1.73m² indicates robust filtration and is the target in longevity practice. Decline below this range, even if still > 60, often signals subclinical kidney stress and should prompt evaluation of blood pressure, glycemic control, and inflammatory markers.
Aggressive (family history of kidney disease or diabetes): > 100 mL/min/1.73m² is a more conservative target if you have genetic predisposition or metabolic risk factors (diabetes, hypertension, obesity). Some evidence supports maintaining higher function to buffer future age-related decline.
A key point: age-adjusted decline is expected and normal, but the rate of decline matters. Someone aged 75 with an eGFR-cystatin-C of 70 mL/min/1.73m² is in better shape than someone aged 45 with an eGFR-cystatin-C of 60, all else equal. When eGFR-cystatin-C and eGFR-creatinine differ by > ~20%, the combined or average eGFR is generally preferred for clinical interpretation.
High eGFR-cystatin-C (> 80 mL/min/1.73m²). This reflects robust glomerular filtration and is the longevity target. It means your kidneys are efficiently clearing small molecules and waste. In young, healthy adults, values > 100 are common. Sustained high eGFR-cystatin-C is strongly associated with lower cardiovascular and all-cause mortality. This range is reassuring for medication safety and suggests your kidneys are not limiting factors in your health trajectory.
Optimal eGFR-cystatin-C (60–80 mL/min/1.73m²). Still within the traditional “normal” range and generally compatible with good health, but the lower end signals gradual age-related decline or metabolic stress. If you are aged > 50 and your eGFR-cystatin-C is trending downward year-on-year, this is the window to address blood pressure (target < 130/80 in most cases), optimize glycemic control (HbA1c < 5.5%), manage inflammatory markers (hs-CRP < 1.0 mg/L), and ensure adequate hydration and protein intake.
Mild decline (eGFR-cystatin-C 45–60 mL/min/1.73m²). This is CKD stage 2 and suggests that some degree of kidney damage or dysfunction is present. Your kidneys can still handle the body's needs, but the safety margin is shrinking. This is when you need closer monitoring, more aggressive management of blood pressure and glucose, and careful review of medications that stress the kidneys (NSAIDs, ACE inhibitors must be dosed carefully, avoided entirely in some cases). Markers like urea and creatinine should be checked alongside cystatin C; if all three point the same direction, the evidence is strong.
Moderate to severe decline (eGFR-cystatin-C < 45 mL/min/1.73m²). This is CKD stage 3 or beyond and signals significant renal dysfunction. You should be under specialist (nephrology) care. Medication choices are heavily constrained; drug dosing must be adjusted; and the risk of progression, cardiovascular events, and metabolic complications rises sharply. Paired testing of creatinine-based eGFR and cystatin-C-based eGFR, plus urea, electrolytes, and phosphate, becomes routine.
Factors that influence eGFR-cystatin-C (confounders). Hyperthyroidism raises cystatin C (lowering apparent eGFR); hypothyroidism lowers it (raising apparent eGFR). Glucocorticoid therapy elevates cystatin C. Severe obesity can raise cystatin C independent of true renal function. Acute illness, dehydration, infection, and high-dose NSAIDs can temporarily reduce eGFR. Recent intense exercise, pregnancy, or malnutrition can also shift values. If your eGFR-cystatin-C is unexpectedly low and you have one of these risk factors, repeat testing after addressing the confounder (treating thyroid disease, stopping NSAIDs, improving hydration) is wise.
Chronic kidney disease (primary renal disease). Diabetes, hypertension, glomerulonephritis, polycystic kidney disease, and chronic pyelonephritis all directly damage the glomerulus or tubules, reducing filtration. This is the most common cause of declining eGFR and is progressive if underlying disease is not controlled.
Hypertension and vascular aging. Sustained high blood pressure damages the delicate blood vessels within the kidney glomerulus, progressively reducing filtration. This is why blood pressure control is so critical in longevity — preventing renal decline slows cardiovascular aging overall.
Diabetes and metabolic dysfunction. Hyperglycemia damages the basement membrane of the glomerulus (diabetic nephropathy), a hallmark of poorly controlled type 2 diabetes. High triglycerides, insulin resistance, and obesity also accelerate renal aging even without overt diabetes.
Medication and toxin exposure. NSAIDs, ACE inhibitors (in certain settings), some antibiotics, contrast dyes, and lithium can all reduce eGFR. Chronic alcohol use and smoking also accelerate renal decline. Regular monitoring is essential if you use any of these.
Age and genetic predisposition. Kidney function naturally declines with age (roughly 0.8 mL/min/1.73m² per year after age 40), but the rate varies. Some families have genetic variants that confer faster decline or higher disease risk. A strong family history of kidney disease or early hypertension warrants closer monitoring and more aggressive intervention targets.
Blood pressure management. Hypertension is the second-leading cause of kidney disease worldwide. Reducing blood pressure to < 130/80 mmHg (or lower if tolerated) slows glomerular sclerosis and reduces proteinuria. ACE inhibitors and ARBs (angiotensin II receptor blockers) are preferred first-line agents because they also provide direct renal protection by reducing glomerular hyperfiltration.
Glycemic control and metabolic health. Keeping fasting glucose < 100 mg/dL (5.6 mmol/L) and HbA1c < 5.5% prevents diabetic nephropathy and metabolic damage to the kidney. This requires sustained attention to refined carbohydrate intake, sleep quality, physical activity, and management of insulin resistance (tracked via fasting insulin and HOMA-IR).
Anti-inflammatory lifestyle. Chronic low-grade inflammation accelerates renal aging independently of diabetes or hypertension. Reducing hs-CRP below 1.0 mg/L through adequate sleep, stress management, exercise, and dietary patterns (Mediterranean or DASH-style eating) protects the kidney vasculature.
Protein and hydration balance. The kidneys filter the byproducts of protein metabolism. In someone with declining kidney function, excessive protein can accelerate decline; moderate protein intake (around 0.8–1.0 g/kg body weight) is generally recommended. Adequate hydration maintains glomerular perfusion and prevents acute kidney injury, but overhydration can also stress the kidneys in advanced disease.
Pharmacology when indicated. SGLT2 inhibitors (dapagliflozin, empagliflozin) have emerged as powerful renal protective agents — they reduce glomerular hyperfiltration, lower blood pressure, and reduce proteinuria even in people without diabetes, slowing eGFR decline. GLP-1 agonists also confer renal benefits through weight loss and metabolic improvement. These are prescription interventions guided by a clinician, not lifestyle-only levers.
The right combination of blood pressure control, glycemic management, inflammation reduction, and (when indicated) targeted pharmacology depends on your genetics, comorbidities, and full biomarker profile — this is the conversation a Loovi longevity doctor maps out in consultation.
A single eGFR-cystatin-C value tells you about kidney filtration, but it does not tell you why filtration might be declining or what to do about it. You need context from complementary markers: creatinine (to assess muscle mass and detect discordance), urea (to evaluate protein metabolism and distinguish prerenal from intrinsic kidney disease), and electrolytes (to track mineral handling). You also need to understand the upstream drivers — is your blood pressure controlled? Is your glucose well-regulated? Are you inflamed? Are you on medications that stress the kidney? These questions require hs-CRP, HbA1c, fasting glucose, and a full medication review. Finally, kidney disease rarely travels alone: it almost always clusters with cardiovascular risk (assessed via ApoB, Lp(a), triglycerides) and metabolic dysfunction (tracked via fasting insulin, triglycerides, and weight).
Loovi's comprehensive biomarker library — 120+ tests annually — maps this full picture. You get eGFR-cystatin-C alongside creatinine-based eGFR, urea, blood pressure, glucose, insulin, lipids, inflammation, and performance metrics. Our longevity doctors then synthesize these into a personalized renal health plan, tailored to your risk profile and goals. From 295 SEK/month, with drop-in testing at 80+ clinics across Sweden, results in 3 days, and unlimited chat support.
eGFR-creatinine depends on muscle turnover, so it overestimates kidney function in athletes and underestimates it in the elderly or sarcopenic. eGFR-cystatin-C is independent of muscle mass and is a stronger predictor of cardiovascular and all-cause mortality. If you have atypical muscle mass, test cystatin-C-based eGFR; if the two diverge by > 20%, the combined (average) eGFR is generally preferred. Swedish nephrology guidelines (LMREV) recommend cystatin-C when muscle mass is uncertain.
This discordance often signals low muscle mass (elderly, sarcopenia, malnutrition) — your true kidney function is probably better than creatinine-based eGFR suggests. It can also reflect recent muscle loss, malignancy, or neurological disease. In this case, cystatin-C-based eGFR is the more accurate estimate. Review your muscle mass, nutritional status, and any recent weight loss with your clinician.
Yes, significantly. Hyperthyroidism raises cystatin C production and lowers apparent eGFR-cystatin-C, even if true kidney function is normal. Hypothyroidism lowers cystatin C and raises apparent eGFR-cystatin-C. If your thyroid status is abnormal, your eGFR-cystatin-C can be misleading. Treat the thyroid disorder first, then retest in 6–8 weeks when thyroid function has stabilized.
Not necessarily. Kidney function declines with age, but the rate of decline matters. If your eGFR is stable or declining slowly and you manage blood pressure, glucose, and inflammation aggressively, you may maintain adequate function throughout life. However, rapid decline (loss of > 2–3 mL/min/1.73m² per year) is a red flag that warrants specialist nephrology evaluation.
Standard vårdcentral testing focuses on creatinine and creatinine-based eGFR. Cystatin-C testing is available at most Swedish clinical labs but is often ordered as a private (out-of-pocket) test unless specifically indicated by your doctor (e.g., muscle wasting, elderly patient, discordant results). Loovi's membership includes cystatin-C and creatinine-based eGFR as part of the comprehensive annual biomarker panel.
eGFR reflects the structural state of the kidney — true glomerular healing is slow. You may see modest improvement (5–10%) within 3–6 months if you aggressively control blood pressure and glucose, but most improvement plateaus after that. The priority is slowing further decline, not recovering lost function. This is why early intervention matters — once kidney damage occurs, it is largely irreversible.
Yes. NSAIDs reduce renal blood flow and can acutely lower eGFR, especially in people with baseline kidney disease, diabetes, or dehydration. Some antibiotics (aminoglycosides, vancomycin, certain fluoroquinolones) are directly nephrotoxic. If you have declining eGFR-cystatin-C and are on chronic NSAIDs or antibiotics, discuss safer alternatives with your clinician.
Severe obesity can raise cystatin C production independent of true renal function, slightly lowering apparent eGFR-cystatin-C. However, this effect is usually modest and does not fully account for very low eGFR values. If you are obese and have low eGFR-cystatin-C, true kidney dysfunction is likely also present — investigate further with urea, electrolytes, and imaging.
CAPA (chronic kidney disease epidemiology collaboration cystatin C and creatinine) combines both cystatin C and creatinine to refine the eGFR estimate and reduce the error that comes from relying on either marker alone. When both markers are available, CAPA often gives the most accurate eGFR, especially in people with discordant values or atypical physiology.
